News headlines about United Therapeutics (NASDAQ:UTHR) have been trending somewhat positive on Wednesday, AlphaOne Sentiment reports. The research firm, a division of Accern, ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. United Therapeutics earned a news impact score of 0.23 on AlphaOne’s scale. AlphaOne also gave media stories about the biotechnology company an impact score of 83 out of 100, meaning that recent news coverage is very likely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Alpha One Sentiment’s analysis:
- United Therapeutics Co. (UTHR) Upgraded by BidAskClub to “Sell” (americanbankingnews.com)
- United Therapeutics Co. (UTHR) CEO Sells $160,704.00 in Stock (americanbankingnews.com)
- United Therapeutics Co. (UTHR) Receives “Sell” Rating from Jefferies Group LLC (americanbankingnews.com)
- United Therapeutics Corporation (NASDAQ:UTHR) Trading Up – Insider Trading Activity (highlightpress.com)
A number of equities analysts have issued reports on the company. BidaskClub upgraded United Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 9th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 target price on shares of United Therapeutics in a research note on Thursday, June 8th. ValuEngine downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Wedbush restated an “outperform” rating and issued a $213.00 target price (down previously from $229.00) on shares of United Therapeutics in a research note on Thursday, April 27th. Finally, Cowen and Company restated a “hold” rating and issued a $121.00 target price on shares of United Therapeutics in a research note on Wednesday, April 26th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $137.09.
United Therapeutics (UTHR) traded down 0.75% during mid-day trading on Wednesday, hitting $130.16. 585,883 shares of the stock were exchanged. United Therapeutics has a 52 week low of $97.52 and a 52 week high of $169.89. The firm has a market capitalization of $5.86 billion, a price-to-earnings ratio of 9.14 and a beta of 1.56. The company’s 50-day moving average price is $123.53 and its 200 day moving average price is $138.51.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. The business had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics had a net margin of 48.21% and a return on equity of 36.38%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.02 earnings per share. Equities research analysts expect that United Therapeutics will post $14.42 EPS for the current year.
In related news, CEO Martine A. Rothblatt sold 1,218 shares of the firm’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $140.16, for a total transaction of $170,714.88. Following the completion of the sale, the chief executive officer now directly owns 1,358 shares in the company, valued at $190,337.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Tommy G. Thompson sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $139.37, for a total transaction of $278,740.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at $278,740. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,238 shares of company stock valued at $2,325,088. 7.50% of the stock is owned by company insiders.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-favorable-news-coverage-very-likely-to-impact-united-therapeutics-uthr-share-price/1909403.html
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.